Icahn School of Medicine at Mount Sinai


 

AACR 2024 Insights: "Linvoseltamab, a BCMA-Targeted BsAb, in Pts With R/R Myeloma Including Difficult-to-Treat Subgroups"

64 views
May 2, 2024
Comments 0
Login to view comments. Click here to Login